NCT03825679: Bacillus

Association Between the Composition of the Bacterial Flora of Thrombi and the Etiological Origin of Cerebral Infarction Treated With Thrombectomy

Completed Last updated 26 November 2021

What this trial tests

trial in Patient With Symptomatic Cerebral Infarction in 45 participants. Completed in 4 January 2020.

Timeline

11 February 2019

Primary endpoint
4 October 2019

4 January 2020

Quick facts

Lead sponsor	Centre Hospitalier Universitaire Dijon
Status	Completed
Study type	OBSERVATIONAL
Enrollment	45
Start date	11 February 2019
Primary completion	4 October 2019
Estimated completion	4 January 2020
Sites	1 location across France

Conditions studied

• Patient With Symptomatic Cerebral Infarction — all drugs for Patient With Symptomatic Cerebral Infarction →
• Patient Who Has Had a Mechanical Thrombectomy — all drugs for Patient Who Has Had a Mechanical Thrombectomy →

Sponsor

Centre Hospitalier Universitaire Dijon

Who can join

18 and older, any sex, with Patient With Symptomatic Cerebral Infarction or Patient Who Has Had a Mechanical Thrombectomy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cerebral infarction is a major health problem. The two most common causes are atherosclerosis (30 to 35%) and cardio-embolic origin (35 to 40%). However, in 25% of cases the cause is undetermined, known as cryptogenic stroke or stroke of undetermined origin. Paroxysmal Atrial Fibrillation appears to cause a significant proportion of these cryptogenic cerebral infarctions. One of the major challenges in the management of cerebral infarctions is the prevention of recurrence. If the cause is atheromatous, treatment is based on platelet antiaggregants and the correction of cardiovascular risk factors. If the cause is atrial fibrillation, the treatment of choice is anticoagulation therapy. Cryptogenic strokes are managed with antiplatelet therapy. In past studies, the thrombi responsible for cerebral infarctions have been analyzed anatomopathologically to see if the composition of the thrombi could help identify the cause of the cerebral infarction. These studies have proved to be contradictory. The composition of the bacterial flora of cerebral infarct thrombi has not yet been studied, apart from some limited data on septic emboli. In myocardial infarction, the cause of which is almost exclusively atheromatous, bacteria of the periodontal flora have been detected in thrombi of ST-segment elevation infarctions. The causes of cerebral infarction are multiple. The hypotheses explored in this study are that there are differences in the composition of the bacterial flora of the thrombus depending on whether the cause is atheromatous or cardio-embolic and that the study of the composition of the thrombus could be used to identify the cardio-embolic cause in patients with cryptogenic cerebral infarction.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.